Lisa M DeAngelis MD

Neurooncology

"Co-Executive Director of the Brain Tumor Center at Memorial Sloan Kettering Chair, Department of Neurology; Lillian Rojtman Berkman Chair in Honor of Jerome B. Posner"

Join to View Full Profile

160 East 53rd StreetNew York, NY 10022

Education & Training

New York Presbyterian Hospital (Cornell Campus)Residency, Neurology, 1985 - 1986
New York Presbyterian Hospital (Columbia Campus)Residency, Neurology, 1983 - 1985
New York Presbyterian Hospital (Columbia Campus)Internship, Internal Medicine, 1980 - 1981
Columbia University Vagelos College of Physicians and SurgeonsClass of 1980

Certifications & Licensure

NY State Medical License 1981 - 2027
NJ State Medical License 2021 - 2023
American Board of Psychiatry and Neurology Neurology

Awards, Honors, & Recognition

New York Magazine: Top Doctors Castle Connolly, 2002-2014
America's Top Doctors Castle Connolly, 2002-2014
Top Doctors: New York Metro Area Castle Connolly, 2002-2014
America's Top Doctors for Cancer Castle Connolly, 2005-2013
Super Doctor SuperDoctors.com
Join now to see all

Clinical Trials

Combination Chemotherapy and Bone Marrow Transplantation or Peripheral Stem Cell Transplantation in Treating Patients With Oligodendroglioma Start of enrollment: 1997 Aug 01
Completed
Phase 2
Erlotinib in Treating Patients With Recurrent Malignant Glioma or Recurrent or Progressive Meningioma Start of enrollment: 2002 Aug 01
Completed
Phase 1, Phase 2
Temozolomide & RT Followed by Dose Dense vs Temozolomide & Retinoic Acid in Pts w/Glioblastoma Start of enrollment: 2005 Aug 09
Completed
Phase 2
Cediranib Maleate and Cilengitide in Treating Patients With Progressive or Recurrent Glioblastoma Start of enrollment: 2010 Mar 01
Completed
Phase 1
Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Recurrent or Progressive Glioblastoma Start of enrollment: 2010 Dec 01
Terminated
Phase 2
Enoxaparin Versus Aspirin in Patients With Cancer and Stroke Start of enrollment: 2012 Dec 18
Completed
Not Applicable
Join now to see all

Publications & Presentations

PubMed

Multicenter Randomized Phase II Study of R-MPV-A Chemoimmunotherapy With or Without Low-Dose Whole-Brain Radiotherapy for Newly-Diagnosed Primary CNS Lymphoma.
Antonio Omuro, Lisa M DeAngelis, Mei-Yin C Polley, Denise Correa, Jeffrey S Wefel
Neuro-Oncology. 2025-11-04
Phase Ib study with expansion of ibrutinib, lenalidomide, and rituximab in patients with relapsed/refractory central nervous system lymphoma.
Lauren R Schaff, Anna F Piotrowski, Elena Pentsova, Igor T Gavrilovic, Andrew Lin
Neuro-Oncology. 2025-09-17
Prospective characterization of germline variants in patients with gliomas and glioneuronal tumors.
Subhiksha Nandakumar, Miika Mehine, Yelena Kemel, Chaitanya Bandlamudi, Diana Mandelker
Acta Neuropathologica. 2025-09-12

Journal Articles

Marked Response of a Hypermutated Adrenocorticotropic Hormone-Secreting Pituitary Carcinoma to Ipilimumab and Nivolumab
Michael Postow, Viviane Tabar, T Jonathan Yang, John Cuaron, Jinru Shia, Lisa M DeAngelis, The Journal of Clinical Endocrinology and Metabolism
Phase I Study of Pomalidomide and Dexamethasone for relapsed/refractory Primary CNS or Vitreo-Retinal Lymphoma
Lisa M DeAngelis, Han W Tun, David Schiff, Kurt A Jaeckle, Christian Grommes, Patrick B Johnston, Craig B Reeder, Thomas E Witzig, Blood

Lectures

Reevaluation of the Frequent Use of PD-1 Checkpoint Inhibitors for Treatment of Glioblastoma
American Academy of Neurology (AAN), San Diego, California - 3/16/2013

Authored Content

Reevaluation of the Frequent Use of PD-1 Checkpoint Inhibitors for Treatment of GlioblastomaMay 2020

Press Mentions

Jeffrey A. Drebin MD, Ph.D., Named Chief Physician Executive of Memorial Sloan Kettering Cancer CenterJune 18th, 2025
Accelerate Cures Through International Collaboration in Clinical Trials: Cancer Moonshot PathwaysAugust 8th, 2022
Memorial Sloan Kettering Ranked Among the Best Hospitals for Cancer Care by U.S. News & World Report for 33 Consecutive YearsJuly 26th, 2022
Join now to see all